Discordant Trial Results Among Issues FDA Bringing To Advisory Panel Review Of Novartis' Afinitor
This article was originally published in The Pink Sheet Daily
Executive Summary
The change in endpoints for the two pivotal studies in neuroendocrine tumors and the fact that they don't support each other will fuel the Oncologic Drugs Advisory Committee discussion of the new indication for everolimus.
You may also be interested in...
Afinitor In Pancreatic Tumors: ODAC Sees Consistent Efficacy, But Favors Limits On Use
The consistency of the progression-free survival benefit with Novartis’ Afinitor (everolimus) led FDA’s Oncologic Drugs Advisory Committee to support the drug’s approval for treatment of advanced pancreatic neuroendocrine tumors (PNET) despite questions about the statistical treatment of data in the pivotal study.
Afinitor In Pancreatic Tumors: ODAC Sees Consistent Efficacy, But Favors Limits On Use
The consistency of the progression-free survival benefit with Novartis’ Afinitor (everolimus) led FDA’s Oncologic Drugs Advisory Committee to support the drug’s approval for treatment of advanced pancreatic neuroendocrine tumors (PNET) despite questions about the statistical treatment of data in the pivotal study.
Pfizer's Sutent, Novartis' Afinitor Earn ODAC Backing For Pancreatic Tumors
Oncologic Drugs Advisory Committee's enthusiasm for sunitinib was tempered by complexities resulting from the pivotal trial's early termination, and the panel urged that everolimus only be used for patients with aggressive disease.